QualityStocks would like to highlight OncoSec Medical Incorporated (OTCBB: ONCS). The company develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy.
In the company’s news yesterday,
OncoSec Medical announced it has initiated the John Wayne Cancer Institute in Santa Monica, Calif., and Lakeland Comprehensive Cancer Center in Lakeland, Fla., as patient enrollment and screening sites for its phase II metastatic melanoma clinical trial (OMS-1100) for the company’s OMS Electro Immunotherapy treatment.
OncoSec Medical plans to enroll 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma. Patients will receive one treatment cycle with three treatments applied to up to four lesions on days one, five, and eight. At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety.
“We are very pleased to have two respected investigators in melanoma clinical research, Drs. Mark Faries and Manuel Molina joining our phase II clinical study,” Punit Dhillon, OncoSec Medical’s president and CEO stated in the press release. “Both the John Wayne Cancer Institute and Lakeland Comprehensive Cancer Center are state of the art clinical sites and represent important centers of excellence that will add value to enrollment targets and expertise by participating in the study.”
Dr. Faries, principal investigator at John Wayne Cancer Institute, noted the ease of which the ElectroImmunotherapy treatment is administered, as well as the therapy’s potential as an alternative therapy.
Dr. Molina, principal investigator at Lakeland Comprehensive Cancer Center, recapped the phase I study, which demonstrated the therapy as safe and with “durable therapeutic benefit.” OMS ElectroImmunotherapy was demonstrated as safe and well-tolerated. Additionally, 53 percent of patients with distant metastatic lesions demonstrated an objective response, with 15 percent of these patients having a complete response to the treatment.
“Advancing into a phase II study is encouraging and is important for validation of results seen in the phase I study. We look forward to participating in this trial,” Dr. Molina stated.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
